Malignant Mesothelioma Therapeutics Pipeline Analysis, 2017 - P&S Market Research


Posted July 27, 2017 by Prajneesh

Malignant mesothelioma is a rare type of cancer that is characterised by tumor formation in the mesothelium, a tissue layer that covers the pleural organs such as heart, abdomen, lungs and other organs.

 
The biggest risk factor of the disease is exposure to asbestos, a silicate mineral. Some of the major symptoms of the disease include cough, shortness of breath and pain in the chest. The symptoms in malignant mesothelioma could take as long as 30 to 50 years to show. Surgery, chemotherapy and radiotherapy are some of the major options available for the treatment of malignant mesothelioma. The prevalence of the disease is not known; however, it is estimated that malignant mesothelioma accounts for approximately 1% of all cancers globally. According to the cancer research, in the U.K., 48% cases of malignant mesothelioma are of people above the age of 75 years.

Explore Report at: https://www.psmarketresearch.com/market-analysis/malignant-mesothelioma-therapeutics-pipeline-analysis

The therapeutics pipeline for malignant mesothelioma is expected to witness considerable growth in the near future on account of increasing exposure of general population to pollutants such as asbestos as a result of rising level of pollution in the environment, eventually leading to increasing prevalence of the disease. Other factors that are expected to contribute to the growth in the therapeutics pipeline of malignant mesothelioma include poor prognosis of the disease, growing healthcare investment on cancer treatments and rising geriatric population.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/malignant-mesothelioma-therapeutics-pipeline-analysis/toc-sample

Some of the major players involved in the development of therapeutics for the treatment of malignant mesothelioma include AstraZeneca plc, Boehringer Ingelheim GmbH, Polaris Pharmaceuticals, Inc., PharmaMar S.A., Bristol-Myers Squibb Company, Ono Pharmaceutical Co., Ltd., Bayer AG, Aduro Biotech, Inc., Calithera Biosciences, Inc., CBT Pharmaceuticals, Inc.
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By P&S Market Research
Business Address New York
Country United States
Categories Business , Medical
Tags malignant mesothelioma therapeutics , malignant mesothelioma therapeutics pipeline , malignant mesothelioma therapeutics pipeline analysis , malignant mesothelioma therapeutics pipeline report
Last Updated July 27, 2017